loading page

Evaluation of endothelial dysfunction in COVID-19 with flow-mediated dilatation
  • +1
  • Aslı Kurtar Mansıroğlu,
  • Hande SEYMEN ,
  • İsa Sincer,
  • Yilmaz Gunes
Aslı Kurtar Mansıroğlu
Bolu Abant İzzet Baysal University
Author Profile
Hande SEYMEN
Bolu Abant İzzet Baysal University
Author Profile
İsa Sincer
Author Profile
Yilmaz Gunes
Bolu Abant İzzet Baysal University
Author Profile

Abstract

Aim: It is a well-known fact that inflammation plays a crucial role in many diseases including COVID-19. Using flow-mediated dilatation (FMD), we aimed to compare the effects of inflammation on endothelial dysfunction in patients with COVID-19 and the control group. Materials and Methods: The present study was conducted on a total of 161 participants, of whom 80 were diagnosed with COVID-19 within the last 6 months (comprising 48 women and 32 men with a mean age of 32.10 ± 5.87 years) and 81 were healthy controls (comprising 45 women and 36 men with a mean age of 30.51 ± 7.33 years). We analyzed the findings of transthoracic echocardiography and FMD in all participants. Results: Except for FMD, there was no statistically significant difference in echocardiographic parameters. (9.52 ± 5.98 vs. 10.53 ± 6.31, p=0.010). In multivariate analysis with the forward stepwise model, FMD was significantly different in the control group compared to the COVID group (1.086 (1.026 - 1.149), p=0.04). Spearman’s correlation test indicated that FMD (r=0.27, p=0.006) had a significantly positive correlation with the presence of COVID. A receiver operating curve analysis revealed that an FMD value of <10.62% was capable of predicting the presence of COVID with a sensitivity and specificity of 64% and 59%, respectively (AUC=0.625, 95% CI, 0.538 - 0.711). Conclusion: The value of FMD decreased significantly in COVID-19 patients compared to the healthy subjects, which may be an early marker for COVID-19 induced endothelial dysfunction. KEYWORDS: COVID-19, endothelial dysfunction, flow-mediated dilatation (FMD